These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3622311)

  • 21. Cyclandelate in the treatment of senile mental changes: a double-blind evaluation.
    Rao DB; Georgiev EL; Paul PD; Guzman AB
    J Am Geriatr Soc; 1977 Dec; 25(12):548-51. PubMed ID: 336670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclandelate: effect on circulatory measurements and exercise tolerance in chronic arterial insufficiency of the lower limbs.
    Reich T
    J Am Geriatr Soc; 1977 May; 25(5):202-5. PubMed ID: 853204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclandelate in diabetic radiculoneuropathy.
    van der Drift JH
    Ann Neurol; 1980 Apr; 7(4):388. PubMed ID: 7377764
    [No Abstract]   [Full Text] [Related]  

  • 24. Multifocal infarct dementia treated by cyclandelate and monitored by quantitative EEG.
    Harding GF; Hall P; Young J; Smith GA
    Angiology; 1978 Feb; 29(2):139-40. PubMed ID: 347986
    [No Abstract]   [Full Text] [Related]  

  • 25. The anti-hypoxaemic effect of cyclandelate in man measured in human volunteers using computer-assisted oculodynamic methodology.
    Schaffler K
    Br J Clin Pract Suppl; 1984; 34():51-7. PubMed ID: 6430324
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of Cyclospasmol upon sensory parameters in patients recovering from cerebrovascular accidents.
    Sourander L; Blakemore CB
    Angiology; 1978 Feb; 29(2):133-8. PubMed ID: 347985
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical value of a combined anti-ischemic and anticholinergic substance with antidepressant properties.
    Brasseur R
    Angiology; 1978 Feb; 29(2):121-32. PubMed ID: 646177
    [No Abstract]   [Full Text] [Related]  

  • 28. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Controlled clinical study of Novodil in the treatment of senile macular lesions].
    Delafoulhouje C; Dalens H; Solé P
    Bull Soc Ophtalmol Fr; 1985 Oct; 85(10):1065-7. PubMed ID: 3915881
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of the cerebral manifestations of arteriosclerosis with cyclandelate.
    Young J; Hall P; Blakemore C
    Br J Psychiatry; 1974 Feb; 124(579):177-80. PubMed ID: 4596673
    [No Abstract]   [Full Text] [Related]  

  • 31. Calcium modulation and clinical effect. Profile of cyclandelate.
    Timmerman H
    Drugs; 1987; 33 Suppl 2():1-4. PubMed ID: 3622303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclandelate and mental functions: a double-blind cross-over trial in normal elderly subjects.
    Judge TG; Urquhart A; Blakemore CB
    Age Ageing; 1973 May; 2(2):121-4. PubMed ID: 4591604
    [No Abstract]   [Full Text] [Related]  

  • 33. [Determination of the anti-anoxia capacity of drugs].
    Truchaud M
    Sem Hop Ther; 1977 Nov; 53(9):425-9. PubMed ID: 341317
    [No Abstract]   [Full Text] [Related]  

  • 34. Cyclandelate: calcium modulation and clinical effects. Proceedings of a symposium. Helsinki, 14-15 November, 1986.
    Drugs; 1987; 33 Suppl 2():1-141. PubMed ID: 3622302
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.
    Siniatchkin M; Gerber WD; Vein A
    Funct Neurol; 1998; 13(1):47-56. PubMed ID: 9584874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
    Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
    Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology and psychopharmacology of dementia--a new study design. 2. Cyclandelate treatment--a placebo-controlled double-blind clinical trial.
    Schellenberg R; Todorova A; Wedekind W; Schober F; Dimpfel W
    Neuropsychobiology; 1997; 35(3):132-42. PubMed ID: 9170118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cyclandelate on perception, memory and cognition in a group of geriatric subjects.
    Aderman M; Giardina WJ; Koreniowski S
    J Am Geriatr Soc; 1972 Jun; 20(6):268-71. PubMed ID: 4555668
    [No Abstract]   [Full Text] [Related]  

  • 40. Cyclandelate in the management of tinnitus: a randomized, placebo-controlled study.
    Hester TO; Theilman G; Green W; Jones RO
    Otolaryngol Head Neck Surg; 1998 Mar; 118(3 Pt 1):329-32. PubMed ID: 9527112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.